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Abstract
Objectives
This study evaluated the prevalence rate of vaso-occlusive crisis (VOC) episodes, rates of
uncomplicated and complicated VOC episodes, and the primary reasons for emergency
room (ER) visits and inpatient admissions for sickle cell disease (SCD) patients.
Methods
The Medicaid Analytic extracts database was used to identify adult SCD patients using
claims from 01JUL2009-31DEC2012. The date of the first observed SCD claim was desig-
nated as the index date. Patients were required to have continuous medical and pharmacy
benefits for�6 months baseline and�12 months follow-up period. Patient demographics,
baseline clinical characteristics, the rate of uncomplicated and complicated VOC (VOC with
concomitant SCD complications) episodes, and reasons for ER visits and inpatient stays
were analyzed descriptively.
Results
A total of 8,521 patients were included in the analysis, with a median age of 30 years. The
average follow-up period was 2.7 years. The rate of VOC episodes anytime in the follow-up
was 3.31 in person-years. During the first-year follow-up period, an average of 2.79 VOC
episodes were identified per SCD patients, with 1.06 VOC episodes treated in inpatient set-
ting and 0.90 VOC episodes in ER without admission. A total of 76,154 VOC episodes were
identified during the entire follow-up period for the overall SCD patients. Most of the VOC
episodes (70.3% [n = 53,523]) were uncomplicated episodes, and 29.7% were complicated
episodes. Using primary diagnosis claims only, the most frequent complications during the
VOC episode were infectious diseases (25.9%), fever (21.8%), and pulmonary disorders
(16.2%). Among ER and hospitalizations related to VOC or SCD complication, ~85.0% had
VOCs as the primary reason for admission; 15.0% had SCD complications as the primary
reason.
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Conclusion
In summary, SCD and its related comorbidities and complications result in high acute health
care utilization. In addition, VOC remains the primary reason for SCD patients’ ER visits and
inpatient admissions.
Introduction
Sickle cell disease (SCD) is a life-threatening genetic disorder affects ~100,000 individuals in the
United States, where it is one of the most common genetic blood disorders [1,2]. Damage to the
red blood cells (RBCs) occurs due to polymerization of deoxygenated hemoglobin S (HbS) and
these damaged cells have abnormal structures as well as expression of adhesion molecules. This
results in hemolytic anemia and the blockade of small blood vessels, which lead to vaso-occlu-
sion and end organ failure [3]. Importantly, multicell adhesion between RBCs, white blood
cells, platelets, and endothelial cells result in painful vaso-occlusive crisis (VOC) [4–6].
The most common sequelae of SCD include VOC episodes, invasive infections, acute chest
syndrome, strokes, and chronic pulmonary hypertension [7]. SCD causes recurrent VOC episodes
as well as increases the risk of infections and other complications that often require emergency
intervention [8]. VOC is a very important complication of SCD: the higher the number of VOCs
experienced by SCD patients, the worse the patient’s quality of life [9,10]. Multicell adhesion is the
driver of VOC, and treatment targeting this adhesion results in more VOC-free days [11].
Some previous studies have examined health care utilizations and the main causes of acute
care for SCD patients. SCD has been associated with high utilization of medical care, such as ER
visits and hospitalization, as observed in a study finding that as high as 53% of SCD patients
who had ER visits subsequently required inpatient stays in hospitals or other treatment facilities
[12]. Studies have shown that VOC is the main cause of most SCD health care utilization or
medical contact, and high health care utilization among SCD patients remains prevalent due to
poor acute pain management [13–15]. A study conducted with Florida Medicaid program data
from 2001–2005 across all patients showed that during the 5-year study period, SCD patients
incurred an average of 3.7 inpatient hospitalizations and 24.1 hospital days, with ~84% attribut-
able to SCD-related diagnoses [16]. Other studies have found that higher health care utilization
in adult SCD patients is associated with a higher risk for mortality, and acute SCD pain episodes
are the most commonly observed cause of inpatient admission in SCD patients [17,18].
Although some studies have looked at the reason for admissions and ER visits in SCD
patients and the rate of pain crisis episodes, very few studies have looked at the rate of SCD
complications in different settings using real-world data. Therefore, using real-world data to
shed light on the more current complications and reasons for health care utilization in adult
SCD patients, this study descriptively evaluates the prevalence rate of VOC, the rate of compli-
cated VOC (VOC with concomitant SCD complications) and uncomplicated VOC episodes,
and the primary reasons for ER and inpatient admissions, with the most recent Medicaid data-
base data available.
Materials and methods
Data sources
This was a retrospective, descriptive study using US Medicaid population data from
01JAN2009-31DEC2013. The Medicaid Analytic extracts (MAX) data system contains
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extensive individual-level information on the characteristics of Medicaid enrollees in all 50
states and the District of Columbia as well as the services used during a calendar year. Specifi-
cally, MAX consists of 1 personal summary file and 4 claims files that provide fee-for-service
claims, managed care encounter data, and premium payments.
The study included fee-for-service patients from all available states and Managed Care
enrollees who resided in 14 states that had relatively complete data (Arizona, California, Indi-
ana, Kansas, Kentucky, Minnesota, Nebraska, New Jersey, New Mexico, New York, Oregon,
Tennessee, Texas, and Virginia). Service use among Managed Care enrollees is captured in
encounter data (ie, data collected from patients when they receive services). Patients who had
dual eligibility with Medicare were not included in this study due to the incomplete informa-
tion in the MAX database.
Patient selection
Adult patients were selected if they had�1 diagnosed claim with SCD (ICD-9-CM code
282.41–282.42, 282.60–282.69) during the identification period (01JUL2009-31DEC2012). The
date of the first observed SCD diagnosis claim was designated as the index date. Patients were
required to have continuous health plan enrollment with medical and pharmacy benefits for
�6 months pre-index date (baseline period) and�12 months post-index date (follow-up
period). Patients were excluded if they were enrolled in a clinical trial during the study period
(identified using ICD-9 codes V70.7).
Baseline measures
Patient socio-demographic and clinical characteristics were measured, including age, sex,
race/ethnicity, geographical region, and Charlson comorbidity index score. In addition, the
rate of inpatient stays and ER visits during the baseline period was assessed.
Outcome measures
The rate of VOC episodes in person-years during the entire follow-up period and the annual
counts of VOC episodes (in total and by place of service in the first year) were assessed. VOC
episodes were defined using the following ICD-9 codes (282.42, 282.62, 282.64, 282.69) from
both primary and secondary claim positions. VOC claims without a 3-day gap were combined
and considered 1 VOC episode. The number of VOC episodes in different settings were also
calculated based on place of service using a hierarchical order: inpatient, ER, outpatient, office,
and other.
Among the total VOC episodes identified in the follow-up period, the percentage of com-
plicated and uncomplicated VOC episodes were examined [19]. A complicated VOC episode
was defined as the presence of a diagnosis of other SCD complications (S1 Table) during the
VOC episode, and uncomplicated VOC was defined as no occurrence of any other SCD com-
plication during the VOC episode. The top 10 concomitant SCD complications (using both
primary and secondary diagnosis claim positions) were identified.
In addition, the total number of ER and hospital visits related to VOC and SCD complica-
tions were examined during the 12-month follow-up period. The primary reasons for SCD-
related ER and hospital visits were assessed based on the primary discharge diagnosis codes,
including VOC (ICD-9-CM: 282.41, 282.42, 282.60–282.69) and SCD complications (S1
Table). Percentage of ER and inpatient visits associated with VOC or SCD complications were
calculated.
Sickle cell disease complications: Prevalence and resource utilization
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Statistical methods
All variables were analyzed descriptively. Percentages and numbers were provided for dichoto-
mous and polychotomous variables. Means and standard deviations were examined for con-
tinuous variables. For length of stay (LOS) of inpatient admission associated with VOC or
SCD complication, median and interquartile range for LOS was also evaluated.
Results
Baseline characteristics
A total of 8,521 patients met the study selection criteria and were included in the analysis (Fig 1).
The mean age of patients was 32.88 years (Standard deviation [SD] = 12.21), and the median age
was 30 years. Patients were mainly from the Northeast region (44.6%). Most patients were female
(67.3%). In addition, a large proportion of patients were African American (74%), and the
remaining 26% patients were either white, Hispanic, other, or recorded as unknown. The mean
Charlson comorbidity index score was 0.65, and the most frequent comorbid conditions during
the baseline period were infectious diseases (19.7%), asthma (10.9%), fever (9.3%), neoplasms
(benign and malignant) (7.2%), upper respiratory tract infections (6.6%), and constipation (5.9%).
During the baseline period, 53.6% (n = 4,563) of the SCD patients had�1 ER visit and
29.8% (n = 2,543) had�1 inpatient admission (Table 1).
Follow-up results
Rate of pain crisis episodes. The mean/(SD) and median length of the follow-up periods
were 972/(378) days and 981 days, respectively. During the entire follow-up, 53.4% of the
Fig 1. Flow chart for patients selection criteria. SCD: Sickle cell disease.
https://doi.org/10.1371/journal.pone.0214355.g001
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8,521 patients had� 1 VOC episode, with a rate of 3.31 VOCs per person-year. During the
first year of the follow-up period, 52.3% of the patients did not have any VOC episode, 14.7%
had 1 VOC episode, 6.7% had 2 VOC episodes and remaining 26.3% had more than 2 VOC
Table 1. Baseline demographic and clinical characteristics.
Patient Characteristics Sickle Cell patients
(Age�18)
(N = 8,521)
n/Mean %/SD
Age (years) 32.88 12.21
Age Group
18–30 4,421 51.9%
31–45 2,521 29.6%
46–64 1,526 17.9%
65+ 53 0.6%
Sex
Male 2,790 32.7%
Female 5,731 67.3%
Race/Ethnicity
White 534 6.3%
Black 6,305 74.0%
Hispanic 862 10.1%
Other 245 2.9%
Unknown 575 6.7%
Geographic Region
Northeast 3,800 44.6%
North Central 843 9.9%
South 2,266 26.6%
West 1,612 18.9%
Charlson Comorbidity Index Score 0.65 1.25
0 5,665 66.5%
1 1,593 18.7%
2–3 941 11.0%
4+ 322 3.8%
Individual Comorbid Conditions�
Neoplasms benign and malignant 617 7.2%
Asthma 928 10.9%
Upper respiratory tract infections 565 6.6%
Fever 792 9.3%
Infectious and parasitic diseases 1,682 19.7%
(Other unknown and unspecified cause of morbidity and mortality) 2,289 26.9%
Constipation 501 5.9%
Baseline All-cause Health Care Resource Utilization for all patients (6 months)
LOS for inpatient stays (days) 4.7 13.0
# of outpatient ER visits 2.3 5.8
Any outpatient ER visit 4,563 53.6%
Any inpatient stay 2,543 29.8%
ER: Emergency room; LOS: Length of stay; n/#: Number; SCD: Sickle cell disease; SD: Standard deviation.
�only categories�5% were reported.
https://doi.org/10.1371/journal.pone.0214355.t001
Sickle cell disease complications: Prevalence and resource utilization
PLOS ONE | https://doi.org/10.1371/journal.pone.0214355 July 5, 2019 5 / 12
episodes (Fig 2). An average of 2.79 VOCs were identified per SCD patient during the first
year of follow-up. Out of the total 2.79 VOCs identified per SCD patient, 1.06 VOC episodes
were in inpatient setting, 0.90 VOC episodes were in an ER setting, 0.51 VOC episodes were in
an outpatient setting, 0.24 VOC episodes were in an office setting, and 0.09 VOC episodes
were in another setting such as pharmacy, school, correctional facilities, etc (Fig 3).
Fig 2. The frequency of VOC during the first year of follow-up. VOC: Vaso-occlusive crisis.
https://doi.org/10.1371/journal.pone.0214355.g002
Fig 3. VOC per patients in different settings during the first year of follow-up. ER: Emergency room; VOC: Vaso-
occlusive crisis; #: Number; Other setting includes pharmacy, school, homeless shelter, prison/correctional facility,
patient’s home, assisted living facility, independent laboratory and unknown setting.
https://doi.org/10.1371/journal.pone.0214355.g003
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Rate of complicated and uncomplicated VOC episodes. During the entire follow-up
period, 76,154 VOC episodes were identified for the 8,521 adult patients. Of the 76,154 VOC
episodes observed, 22,631 (29.7%) were complicated VOCs and 53,523 (70.3%) were uncom-
plicated VOCs, respectively. Of the 22,631 complicated VOC episodes, the top associated con-
comitant SCD complications (according to primary diagnosis claims only) included infectious
diseases (25.9%), fever (21.8%), pulmonary disorders (16.2%), cerebrovascular conditions
(8.5%), and thrombosis/deep vein thrombosis (8.2%). While the top associated concomitant
SCD complications (according to both primary and secondary diagnosis claim positions) were
pulmonary disorders (76.1%), infectious diseases (55.1%), fever (45.4%), aseptic (avascular)
bone necrosis (29.7%), and cerebrovascular conditions (20.5%) (Fig 4).
Primary reasons for SCD-related ER visits and hospitalization. Of the 8,521 adult SCD
patients included in the study, a total of 3,493 ER visits related to VOC or SCD complications
were identified during the 1-year follow-up period. Similarly, a total of 1,705 hospital visits
related to VOC or SCD complications during the 1-year follow-up period were identified.
Approximately 85.0% of SCD-related ER visits (n = 2,982) or hospitalizations (n = 1,449) had
VOC as the primary reason for admission; 15.0% of the SCD-related ER visits (n = 511 or hos-
pitalizations (n = 256) had SCD complications as the primary reason (Fig 5). Of the 256 hospi-
talizations with an SCD complication as the primary reason, the most common complications
were infectious and parasitic diseases (35.5%) and cerebrovascular complications such as sei-
zures (12.5%) and stroke (9.8%). The mean/(SD) and median/(interquartile) for LOS were 7/
(7.4) days and 5/(5) days for VOC-related admissions; the mean/(SD) and median/(interquar-
tile) for LOS were 9.7/(11.4) days and 6/(7) days for SCD-complication-related admissions.
Discussion
Using the most recent Medicaid data, this study evaluates the rate of SCD complications in dif-
ferent settings. In addition, the study evaluates the prevalence rate of VOC, the rate of compli-
cated VOC (VOC with concomitant SCD complications) and uncomplicated VOC episodes,
and the primary reasons for ER and inpatient admissions.
Over 76,000 VOC episodes were observed during the entire follow-up for the 8,521 adult
SCD patients. The median age of the study population was 33 years, indicating that ~50% of
the population was aged between 18–33 years. Studies have shown that young patients aged
18–33 years have had the highest mean annual ER visits compared with other age groups [14,
20–22], and more than 50% of our study population were in this age group. Further studies
can be examined to evaluate the relationship between economic burden from VOC and age
groups.
Studies have found that VOC, which commonly presents as a pain crisis, is the most com-
mon reason for hospitalization and ER visits in SCD patients [13,14, 23]. Another study
showed that >90% of acute hospital admissions of SCD patients were because of severe and
unpredictable pain crises [24]. Those findings accord with this study, which observed that
VOCs were responsible for 85% of acute medical care for SCD patients, such as ER visits and
hospitalization. Moreover, the mean LOS of inpatient visits for SCD or VOC-related admis-
sions was 7 days and 9.7 days for SCD-complication-related admissions, respectively. Simi-
larly, a previous study that examined management approaches for uncomplicated VOC
observed an average LOS of 7.8 days for uncomplicated SCD admissions [25].
Studies have shown that VOC episodes in adult SCD patients are actually far more preva-
lent and severe than what is reported because VOCs are mostly managed at home; this under-
reporting most likely also indicates an underestimation of VOC prevalence and
undertreatment [13]. In the case of this study, discrete VOC episodes within a 3-day gap were
Sickle cell disease complications: Prevalence and resource utilization
PLOS ONE | https://doi.org/10.1371/journal.pone.0214355 July 5, 2019 7 / 12
recorded as a single episode (eg, multiple ER admissions resulting in hospitalization within a
3-day period would still be calculated as an admission). Per patient we observed an average of
9 episodes requiring health care visits during the entire follow-up period of 2.7 years (ie, an
average of about 3.3 VOCs per patient per year). In this study, VOC episodes were more com-
monly observed in acute settings, such as inpatient and ER, compared to other settings like
outpatient.
Moreover, studies have observed infectious disease and pulmonary disease as common
complications for SCD patients [13, 14]. Those findings accord with this study, which showed
Fig 4. SCD-related complications and concomitant comorbidities using primary and secondary diagnosis during the entire follow-up
period. DVT: Deep vein thrombosis; SCD: Sickle cell disease.
https://doi.org/10.1371/journal.pone.0214355.g004
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that infectious diseases, fever, and pulmonary disorders were the most common concomitant
SCD complications observed during the follow-up period.
Fig 5. Primary reason for ER visits and inpatient stay during the first year of follow-up. SCD: Sickle cell disease; VOC:
Vaso-occlusive crisis.
https://doi.org/10.1371/journal.pone.0214355.g005
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Limitations
Although claims data are valuable for the efficient and effective examination of health care out-
comes, they are collected for payment and not research. Therefore, certain limitations are asso-
ciated with their use. For instance, the presence of a diagnosis code on a medical claim does
not indicate a positive presence of disease, as the diagnosis code may be incorrectly coded or
included as rule-out criteria rather than actual disease.
In addition, this study was conducted on a population that may preclude generalizations to
other populations. Specifically, the study setting was within the Medicaid population, which
consists of people with disabilities, children of low-income families, pregnant women, parents
of Medicaid-eligible children who meet certain low-income requirements, and low-income
seniors. These populations are more likely than the general population to have unmet health
care service needs.
Some data exclusions were also limitations. We excluded individuals with dual eligibility
for both Medicaid and Medicare, for instance, since the data of these observations are not
complete. Additionally, due to limited availability, the data of managed care plan patients only
included 14 states, and study periods up to 31DEC2013 were the most recent data at the time
of the study.
Conclusions
In a real-world setting, SCD and its related complications result in high acute health care utili-
zation, and VOCs remain the primary reason for SCD patients’ ER visits and inpatient admis-
sions. Our study shows that there is a great need for symptomatic and preventive management
of VOC to the reduce burden of VOC-related healthcare utilizations. Recommendations that
would alleviate this burden in SCD patients should focus on supportive management (which
entails basic requirements for healthy living), preventive management (which includes the use
of target therapeutics and vaccines to prevent infections), and curative management [26]. A
combination of these measures will increase the likelihood of adequate treatment of VOC
patients and help to prevent the complications and comorbidities associated with SCD.
Supporting information
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